NCT04461509 2026-02-20
High Resolution, 18F-PSMA PET-MRI Before Prostate Cancer HIFU or Radical Prostatectomy
Cedars-Sinai Medical Center
Phase 2 Completed
Clinical Trials
25 trialsOTHER × 2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid × Clear all
NCT03861676 2026-02-13
Image-guided Focal Brachytherapy Utilizing Combined 18F-DCFPyl PET/CT
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase EARLY_PHASE1 Recruiting
NCT04573231 2026-02-05
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
University of Wisconsin, Madison
Phase 2 Recruiting
NCT06085664 2026-01-15
A Pilot Presurgical Trial of REGN5678 (Anti-PSMA x CD28) in Patients With High-risk, Localized Prostate Cancer Followed by Radical Prostatectomy
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT05470699 2025-12-17
RefleXion PET/CT Imaging Performance in Patients With Prostate Cancer
City of Hope Medical Center
Phase NA Active not recruiting
NCT05919329 2025-10-24
Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy
OHSU Knight Cancer Institute
Phase 4 Recruiting
NCT04910425 2025-10-21
PSMA-Targeted 18F-DCFPyL PET/MRI for the Detection of Prostate Cancer
Northwestern University
Phase 2 Withdrawn
NCT06499870 2025-10-21
Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial
Northwestern University
Phase 2 Recruiting
NCT04687969 2025-09-25
Multimodal Machine Learning Characterization of Solid Tumors
Massachusetts General Hospital
Active not recruiting
NCT06361810 2025-08-19
PSMA Therapy and Immunotherapy in Kidney Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Withdrawn
NCT05095519 2025-07-16
HepaSMART
Peter MacCallum Cancer Centre, Australia
Phase 2 Active not recruiting
NCT06904313 2025-06-04
Ultralow Dose PET Imaging for PSMA Expression
Nuclear Imaging Institute
Phase 2 Recruiting
NCT03392181 2025-05-23
PET/MRI for the Staging of Newly Diagnosed Prostate Cancer
Northwestern University
Phase EARLY_PHASE1 Active not recruiting
NCT03471650 2025-03-10
Study of PSMA-targeted 18F-DCFPyL PET/CT for the Detection of Clinically Significant Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Active not recruiting
NCT05568537 2025-01-03
Prostate MRI and Pylarify PSMA PET/CT
Corewell Health East
Phase 4 Withdrawn
NCT04809584 2024-12-19
18F-DCFPyL PET/MRI in Regional Nodal&Distant Metastases Detection in Intermediate &HR Prostate Cancer
Stanford University
Approved for marketing
NCT04727736 2024-02-15
18F-DCFPyL Positron Emission Tomography (PET) in Intermediate or High Risk Prostate Cancer
University of Pittsburgh
Phase 2 Terminated
NCT03619655 2023-10-31
Assessment of Multi-Modality Quantitative Imaging for Evaluation of Response of Metastatic Prostate Cancer to Therapy
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Terminated
NCT04457245 2023-01-17
PSMA-dRT
Jonsson Comprehensive Cancer Center
Phase 3 Terminated
NCT03542773 2023-01-11
Targeted Imaging of Glutamate Carboxypeptidase II With DCFPyL-PET
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT03501940 2022-01-21
F18 DCFPyL PET/CT in Imaging Participants With Recurrent Prostate Cancer
Stanford University
No longer available
NCT03793543 2021-12-15
Test-Retest Reproducibility of 18F-DCFPyL PET/CT in the Evaluation of Patients With Metastatic Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT02151760 2020-05-07
Study of 18F-DCFPyL, a Second Generation Low-molecular Weight PSMA-based PET Radiotracer, in Patients With Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT03497377 2020-05-07
Evaluation of 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT02687139 2020-04-29
Study of PSMA-targeted 18F-DCFPyL PET/CT in the Evaluation of Patients With Renal Cell Carcinoma
Johns Hopkins University
Phase NA Completed